Incysus Seeks FDA Approval to Start Blood Cancer Trials for Its γδ T-Cell Immunotherapy – Lymphoma News Today
|
Incysus Seeks FDA Approval to Start Blood Cancer Trials for Its γδ T-Cell Immunotherapy
Lymphoma News Today Incysus has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to start clinical development of its expanded and activated allogeneic gamma-delta (γδ) T-cell therapy for patients with blood cancers who … |
|
Incysus Seeks FDA Approval to Start Blood Cancer Trials for Its γδ T-Cell Immunotherapy
Lymphoma News Today Incysus has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to start clinical development of its expanded and activated allogeneic gamma-delta (γδ) T-cell therapy for patients with blood cancers who … |
OncLive |
Immunotherapy in the Peri-Operative Setting of HNSCC
OncLive And I think in the next year, we’re going to get a flurry of safety data on combinations of immunotherapy and radiation that will then empower efficacy design studies to ask, how should we do that? Should it be in combination with platinum and radiation? |
Investor’s Business Daily |
Why Bluebird’s Downgrade Sent These Two Rivals Skyrocketing
Investor’s Business Daily Crispr rallied 4.6%, near 18.70, as Editas popped 3.7%, near 24.90, on Bluebird’s downgrade. All three are working on therapies to treat sickle cell disease, a group of inherited blood disorders. Therapies from Crispr and Editas are showing promise … |